Tirzepatide vs semaglutide weight loss — complete comparison of SURMOUNT-1 (~22%) vs STEP-1 (~15%) data, dual GIP/GLP-1 mechanism, week-by-week timeline, nausea rates, and cardiovascular outcomes.